HomeInsightsStock Comparison

Acutaas Chemicals Ltd vs Eris Lifesciences Ltd Stock Comparison

Acutaas Chemicals Ltd vs Eris Lifesciences Ltd Stock Comparison

Last Updated on: Dec 18, 2025

Key Highlights

  • The Latest Trading Price of Acutaas Chemicals Ltd is ₹ 1630 as of 18 Dec 15:40.
  • The P/E Ratio of Acutaas Chemicals Ltd changed from 50.6 on March 2022 to 125.9 on March 2025 . This represents a CAGR of 25.59% over 4 yearsThe P/E Ratio of ERIS Lifesciences Ltd changed from 16.9 on March 2020 to 54.8 on March 2025 . This represents a CAGR of 21.66% over 6 years.
  • The Market Cap of Acutaas Chemicals Ltd changed from ₹ 3642 crore on March 2022 to ₹ 9994 crore on March 2025 . This represents a CAGR of 28.70% over 4 yearsThe Market Cap of ERIS Lifesciences Ltd changed from ₹ 5003 crore on March 2020 to ₹ 19287 crore on March 2025 . This represents a CAGR of 25.22% over 6 years.
  • The revenue of Acutaas Chemicals Ltd for the Sep '25 is ₹ 316.03 crore as compare to the Jun '25 revenue of ₹ 223.17 crore. This represent the growth of 41.61% The revenue of ERIS Lifesciences Ltd for the Sep '25 is ₹ 795.5 crore as compare to the Jun '25 revenue of ₹ 776.58 crore. This represent the growth of 2.44%.
  • The ebitda of Acutaas Chemicals Ltd for the Sep '25 is ₹ 105.16 crore as compare to the Jun '25 ebitda of ₹ 66.85 crore. This represent the growth of 57.31% The ebitda of ERIS Lifesciences Ltd for the Sep '25 is ₹ 291.3 crore as compare to the Jun '25 ebitda of ₹ 280.29 crore. This represent the growth of 3.93%.
  • The net profit of Acutaas Chemicals Ltd changed from ₹ 22.24 crore to ₹ 71.86 crore over 10 quarters. This represents a CAGR of 59.86% The net profit of ERIS Lifesciences Ltd changed from ₹ 93.65 crore to ₹ 134.47 crore over 10 quarters. This represents a CAGR of 15.57% .
  • The Dividend Payout of Acutaas Chemicals Ltd changed from 15.19 % on March 2022 to 7.7 % on March 2025 . This represents a CAGR of -15.62% over 4 yearsThe Dividend Payout of ERIS Lifesciences Ltd changed from 13.76 % on March 2020 to 129.35 % on March 2025 . This represents a CAGR of 45.28% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Acutaas Chemicals Ltd

  • Ami Organics Limited was initially formed as a partnership firm in the name of 'Ami Organics' with effect from 03 January, 2004 at Surat, India.
  • The Firm converted into a Private Limited Company under the name of 'Ami Organics Private Limited' with a Certificate of Incorporation dated 12 June, 2007.
  • Subsequently, the Company was converted into a Public Limited Company, following which the Company's name was changed to 'Ami Organics Limited', and a fresh Certificate of Incorporation was issued by RoC on April 18, 2018. The Company is engaged in business of drugs intermediate chemicals and related activities.
  • The Company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.
  • The Company Implemented the Integrated Management System (IMS) in 2011; it incorporated Ami OncoTheranostics, LLC in Delware, USA along with Photolitec LLC as a 50-50 JV in 2015.

About ERIS Lifesciences Ltd

  • Eris Lifesciences Limited was incorporated on January 25, 2007.
  • Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
  • Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
  • The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
  • It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors.

Acutaas Chemicals Ltd News Hub

News

Acutaas Chemicals hits record high after reporting strong Q2 numbers

Profit before tax (PBT) soared 92.19% YoY to Rs 96.17 crore in Q2 FY26. In Q2 FY26, EBITDA...

Read more

17 Oct 2025 13:59

News

Acutaas Chemicals to conduct board meeting

Acutaas Chemicals will hold a meeting of the Board of Directors of the Company on 17 Octob...

Read more

10 Oct 2025 17:08

News

Acutaas Chemicals to convene AGM

Acutaas Chemicals announced that the Annual General Meeting(AGM) of the company will be he...

Read more

03 Sep 2025 15:55

News

Acutaas Chemicals spurts after Q1 PAT surges 199% YoY

In Q1 FY26, Acutaas Chemicals reported a 17.3% rise in consolidated revenue from operation...

Read more

31 Jul 2025 14:23

News

Acutaas Chemicals to discuss results

Acutaas Chemicals will hold a meeting of the Board of Directors of the Company on 30 July ...

Read more

25 Jul 2025 11:10

News

Baba Advance Materials enters in JV agreement with J & Materials Co.

Baba Advance Materials (BAML), a wholly owned subsidiary company of Acutaas Chemicals has ...

Read more

27 Jun 2025 19:30

ERIS Lifesciences Ltd News Hub

News

Volumes spurt at ERIS Lifesciences Ltd counter

Tata Teleservices (Maharashtra) Ltd, Anand Rathi Wealth Ltd, Triveni Engineering and Indus...

Read more

09 Dec 2025 14:30

News

ERIS Lifesciences board approves acquisition of balance 30% stake in Swiss Parenterals

The board of ERIS Lifesciences at its meeting held on 24 November 2025 has approved the ac...

Read more

24 Nov 2025 18:35

News

ERIS Lifesciences to convene board meeting

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 24 Novem...

Read more

19 Nov 2025 17:36

News

ERIS Lifesciences to table results

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 12 Novem...

Read more

10 Nov 2025 11:36

News

Eris Lifesciences allots 6,761 equity shares under ESOP

Eris Lifesciences has allotted 6,761 equity shares under ESOP on 30 August 2025. The paid-...

Read more

30 Aug 2025 15:58

News

Eris Lifesciences receives Brazil's Anvisa approval for Ahmedabad unit

Eris Lifesciences announced that one of its sterile injectable manufacturing facilities in...

Read more

26 Aug 2025 13:23

SWOT Analysis Of Acutaas Chemicals Ltd

Strength

5

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of ERIS Lifesciences Ltd

Strength

4

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Acutaas Chemicals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for ERIS Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Acutaas Chemicals Ltd and ERIS Lifesciences Ltd

Which company has a larger market capitalization, Acutaas Chemicals Ltd or ERIS Lifesciences Ltd?

Market cap of Acutaas Chemicals Ltd is 13,596 Cr while Market cap of ERIS Lifesciences Ltd is 21,288 Cr

What are the key factors driving the stock performance of Acutaas Chemicals Ltd and ERIS Lifesciences Ltd?

The stock performance of Acutaas Chemicals Ltd and ERIS Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Acutaas Chemicals Ltd and ERIS Lifesciences Ltd?

As of December 18, 2025, the Acutaas Chemicals Ltd stock price is INR ₹1660.75. On the other hand, ERIS Lifesciences Ltd stock price is INR ₹1562.85.

How do dividend payouts of Acutaas Chemicals Ltd and ERIS Lifesciences Ltd compare?

To compare the dividend payouts of Acutaas Chemicals Ltd and ERIS Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions